Science & Pipeline
BioShin is a clinical-stage company focused on advancing therapies in China and the Asia-Pacific region for which there are currently limited adequate treatment options.
Our current clinical programs span a range of innovative, late-stage product candidates targeting neurological diseases. BioShin combines internal assets with intellectual property licensed from leading biopharma companies and academic institutions to rapidly progress multiple compounds in clinical trials across three platforms: calcitonin gene-related peptide (CGRP) receptor antagonism, glutamate modulation, and myeloperoxidase (MPO) inhibition.
Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drug candidates that act to block the pain signaling pathway. Oral CGRP antagonists have the potential to be best in class therapy for migraine and other CGRP-mediated disorders.
Glutamate is present in 90% of brain synapses, and plays a critical role in neurotransmission.